Moderna Ends IP Dispute with $2.25B Payout
Moderna has entered into a massive $2.25 billion global settlement with Genevant Sciences and Arbutus Biopharma. The deal resolves a long-running intellectual property dispute over the lipid nanoparticle (LNP) delivery technology crucial to mRNA vaccines. The settlement removes a major legal overhang for Moderna.
The settlement's structure includes a $950 million non-contingent payment from Moderna due in July 2026. An additional $1.3 billion is contingent on an appellate court ruling against Moderna's defense under U.S. federal statute 28 U.S.C. § 1498. Moderna’s key legal argument for the contingent portion claimed it had government-contractor immunity. This statute can shield companies from patent liability for sales made under federal government contracts, with Moderna arguing taxpayers should assume the liability. The $1.3 billion payment hinges on the Federal Circuit rejecting this defense. The dispute began when Arbutus and Genevant sued Moderna in a Delaware federal court in February 2022. The legal battle later escalated significantly, with five international lawsuits filed across 30 countries by March 2025, all targeting the unauthorized use of the LNP technology in Moderna's vaccines. For Moderna, the total payout represents an effective royalty rate of less than 2% to 5% on approximately $48 billion in cumulative global sales. Following the announcement, Moderna's (MRNA) stock surged roughly 10% in after-hours trading, though the company lowered its year-end 2026 cash guidance by $1 billion to a range of $4.5 billion to $5.0 billion. The news caused Arbutus Biopharma (ABUS) shares to jump 24% and shares of Genevant's parent company, Roivant Sciences (ROIV), to rise 6.5%. Arbutus is entitled to 20% of the settlement proceeds after litigation costs. [cite: 10, 22
